Follow us on Twitter!   

Challenges and Future Directions of the European Pediatric PVD Network

  • Identification of valid treatment goals in pediatric PAH.
  • Regulatory requirements, patient recruitment and retention, clinical trial endpoints for pediatric PAH trials.
  • Need to conduct multicenter studies and to establish new registries for pediatric PH.
  • Initiation of a prospective multicenter study on early combination therapy in pediatric PAH including a comparative group (early combined dual or triple combination, rapid sequence of 2 agents).
  • When and how to perform a Potts shunt procedure (surgery, intervention?) for advanced PAH, and how to combine this pressure-unloading shunt with combination pharmacotherapy?
  • Initiation of investigator-initiated pilot and/or industry-sponsored phase 2/3 studies on the safety and efficacy of new compounds recently published/approved for adult PAH (macitentan, riociguat, selexipag, treprostinil).

Challenges and Future Directions of the European Pediatric PVD Network

Follow us on Twitter!

  • Identification of valid treatment goals in pediatric PAH.
  • Regulatory requirements, patient recruitment and retention, clinical trial endpoints for pediatric PAH trials.
  • Need to conduct multicenter studies and to establish new registries for pediatric PH.
  • Initiation of a prospective multicenter study on early combination therapy in pediatric PAH including a comparative group (early combined dual or triple combination, rapid sequence of 2 agents).
  • When and how to perform a Potts shunt procedure (surgery, intervention?) for advanced PAH, and how to combine this pressure-unloading shunt with combination pharmacotherapy?
  • Initiation of investigator-initiated pilot and/or industry-sponsored phase 2/3 studies on the safety and efficacy of new compounds recently published/approved for adult PAH (macitentan, riociguat, selexipag, treprostinil).

Featured Meetings

Featured Meetings

2nd International Pulmonary Hypertension/Heart Failure Symposium

June 11 – 12, 2022 (1.5 day meeting), Berlin, Germany

Venue: GLS Campus, Kastanienallee 82, Berlin, Germany

LEARN MORE

PH and Heart Failure – we are searching for a Cure

The European Pediatric Pulmonary Vascular Disease Network is a non-profit organization that strives to define and develop diagnostic methods and new therapies (pharmacotherapy, critical care, VAD/ECMO, cahter/surgical interventions, bilateral lung transplantation) in all forms of pediatric hypertensive vascular disease (PHVD):

The forms of PHVD include pulmonary arterial hypertension (e.g., idiopathic PAH, hereditary PAH, and pulmonary hypertension (PH) associated with congenital heart disease (PH-CHD)), PH associated with chronic lung disease (PH-nCLD/bronchopulmonary dysplasia), persistent pulmonary hypertension of the newborn (PPHN), pulmonary venoocclusive disease (PVOD), pulmonary capillary hemangiomatosis, among others. Moreover, the network adresses the detrimental cardiac dysfunction and heart failure associated with PH, in particular, the RV – pulmonary artery (PA) unit, right ventricular failure, RV – LV interaction and LV compression, right (RA) and left atrial (LA) hypertension.